Nigerian parents and caregivers face an urgent warning this week after the National Agency for Food and Drug Administration and Control issued Public Alert No. 028/2026, flagging a children's ibuprofen oral suspension that has been recalled in the United States due to potential contamination with foreign material — a development that raises immediate concern about whether the same product has entered Nigeria's medicine supply chain.
Ibuprofen oral suspension is among the most widely used over-the-counter fever and pain relief medications for children under 12 across Nigeria, dispensed daily in patent medicine stores, community pharmacies, and primary healthcare centres from Kano to Port Harcourt. In a country where an estimated 40 million children under five are treated for febrile illnesses each year — many of them at home with medicines purchased informally — a contamination alert of this nature carries risks well beyond the formal retail sector.
NAFDAC's alert, designated the 28th public safety notice issued in 2026, follows a recall initiated in the United States over the presence of foreign material in the suspension. Foreign material contamination in liquid oral medicines poses particular dangers for young children, whose smaller airways and digestive tracts are far more vulnerable to physical obstruction or internal injury than those of adults.
Nigeria's drug market is deeply porous, with pharmaceuticals frequently entering through informal channels long after official import windows close. Products recalled in the United States or Europe have historically appeared on Nigerian shelves — in Onitsha's Bridge Head Market, Kano's Kantin Kwari, and Lagos Island's pharmaceutical belt — weeks or months after their withdrawal elsewhere. This pattern is precisely why NAFDAC has developed its public alert system: to intercept products that regulation at the border may have missed.
NAFDAC directed consumers, patent medicine dealers, pharmacists, and healthcare providers to immediately check any children's ibuprofen oral suspension in their possession, cross-referencing batch numbers and product details against those specified in the alert. The agency also instructed that any suspected affected product should not be administered to children and should be reported to the nearest NAFDAC office or through its consumer reporting channels without delay.
Nigerians should expect NAFDAC to intensify market surveillance in the coming days, particularly at open drug markets and wholesale pharmaceutical hubs in Lagos, Abuja, Onitsha, and Kano. Parents who have recently purchased any children's ibuprofen suspension — regardless of brand — should check the product packaging carefully and seek pharmacist guidance before giving it to a child. The agency's full product details and batch information are available on the NAFDAC website at nafdac.gov.ng.
Until every bottle flagged by this recall is off Nigerian shelves and out of Nigerian homes, no parent should assume a familiar medicine is automatically a safe one.
